Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Multicenter retrospective study of ramucirumab-containing chemotherapy for gastrointestinal neuroendocrine carcinoma patients previously treated with platinum-based chemotherapy: RAM-NEC study (WJOG13420G).
Authors
Hidekazu Hirano
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
Hidekazu Hirano , Yuki Matsubara , Toshiki Masuishi , Saori Mishima , Mitsuhiro Furuta , Tomoyuki Otsuka , Kenta Kawasaki , Takeshi Kawakami , Kazuhiro Yanagihara , Takaya Shimura , Masato Komoda , Kozue Murayama , Keiko Minashi , Yoshiyuki Yamamoto , Yudai Shinohara , Shinichi Nishina , Nobuyuki Musha , Kyoko Kato , Isao Oze , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.511
Abstract #
511
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.
First Author: Haeseong Park
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
First Author: Hiromichi Shirasu
Poster
2019 Gastrointestinal Cancers Symposium
Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in first line metastatic pancreatic cancer (MPC): Updated results.
First Author: Vincent J. Picozzi